Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP.AVXL · Entity 6086 | PFO & Treasurer | September 24, 2026 | September 29, 2026 |
| DESTINY MEDIA TECHNOLOGIES INCDSNY · Entity 8237 | Chief Financial Officer | October 03, 2019 | October 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAVEX LIFE SCIENCES CORP.
Report date September 24, 2026 · Filed September 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.09 · Expires 2032-06-27 | Direct | 20,000 |
Reported balance
After 2026-09-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-24 · Grant · Acquired 20,000 · Balance 20,000 F1: As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.57 · Expires 2033-03-31 | Direct | 25,000 |
Reported balance
After 2026-09-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-24 · Grant · Acquired 25,000 · Balance 25,000 F1: As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.36 · Expires 2034-02-20 | Direct | 25,000 |
Reported balance
After 2026-09-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-24 · Grant · Acquired 25,000 · Balance 25,000 F1: As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.58 · Expires 2035-03-31 | Direct | 25,000 |
Reported balance
After 2026-09-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-24 · Grant · Acquired 25,000 · Balance 25,000 F1: As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025.
DESTINY MEDIA TECHNOLOGIES INC
Report date October 03, 2019 · Filed October 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2022-12-13 | Direct | 30,000 |
Reported balance
After 2019-10-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-03 · Grant · Acquired 30,000 · Balance 30,000 F1: The reporting person agreed to cancellation of options granted on December 13, 2017 and amended June 25, 2019 in exchange for a new option having a lower exercise price. F2: The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2022-12-13 | Direct | 0 |
Reported balance
After 2019-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-03 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: The reporting person agreed to cancellation of options granted on December 13, 2017 and amended June 25, 2019 in exchange for a new option having a lower exercise price. F2: The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2022-12-13 | Direct | 0 |
Reported balance
After 2019-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: The reporting person agreed to cancellation of options granted on December 13, 2017 and amended June 25, 2019 in exchange for a new option having a lower exercise price. F2: The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person agreed to cancellation of options granted on December 13, 2017 and amended June 25, 2019 in exchange for a new option having a lower exercise price.
F2: The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 29, 2026 01:36 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001731122-26-001296 · ownership.xml · derivative · entry 4 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-03-31 F1 · balance_after: As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025. Read SEC document |
| September 24, 2026 Filed Sep 29, 2026 01:36 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.36 | $0.00 |
DisclosureSEC source: 0001731122-26-001296 · ownership.xml · derivative · entry 3 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-02-20 F1 · balance_after: As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025. Read SEC document |
| September 24, 2026 Filed Sep 29, 2026 01:36 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0001731122-26-001296 · ownership.xml · derivative · entry 2 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-03-31 F1 · balance_after: As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025. Read SEC document |
| September 24, 2026 Filed Sep 29, 2026 01:36 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001731122-26-001296 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-27 F1 · balance_after: As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025. Read SEC document |
| January 06, 2026 Filed Jan 9, 2026 22:26 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001731122-26-000035 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-03-31 F1 · shares: On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a second regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares. Read SEC document |
| October 02, 2025 Filed Oct 4, 2025 00:42 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $5.36 | $0.00 |
DisclosureSEC source: 0001731122-25-001355 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 12,500 shares Expires 2034-02-20 F1 · shares: On February 20, 2024, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Readout of AV3-71-SZ-001 schizophrenia study. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 21:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001731122-25-001168 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-03-31 F1 · shares: On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of preclinical blarcamesine prevention AD data. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares. Read SEC document |
| April 28, 2025 Filed May 1, 2025 00:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0001731122-25-000655 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-03-31 F1 · shares: On March 31, 2023, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was completion of enrollment of ANAVEX3-71 Phase 2 clinical trial in Schizophrenia. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 02:12 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0001731122-25-000095 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-03-31 F1 · shares: On March 31, 2023, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of AD-004 Alzheimer's disease study. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares. Read SEC document |
| December 19, 2024 Filed Dec 24, 2024 00:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $5.36 | $0.00 |
DisclosureSEC source: 0001731122-24-002045 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-02-20 F1 · shares: On February 20, 2024, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was regulatory submission of AD-004 for Alzheimer's disease (US or EU). The performance criteria for this milestone was met with the acceptance of the MAA filing by the EMA, resulting in vesting of the option as to 12,500 shares. Read SEC document |
| November 19, 2024 Filed Dec 7, 2024 02:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001731122-24-001952 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-27 F1 · shares: On June 27, 2022, the reporting person was granted an option to purchase 40,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included completion of the Clinical Study Report for Phase 2a/b AD-004 Alzheimer's disease study. The performance criteria for this milestone was met in connection with the Marketing Authorization Application filing, resulting in vesting of the option as to 10,000 shares. Read SEC document |
| January 02, 2024 Filed Jan 13, 2024 01:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001731122-24-000069 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-27 F1 · balance_after: On June 27, 2022, the reporting person was granted an option to purchase 40,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 10,000 shares. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:36 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001731122-21-001302 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-08-02 F1 · derivative.exercise_date: The options shall vest upon achieving a key enrollment milestone in a late stage clinical study. Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 01:45 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $5.92 | $0.00 |
DisclosureSEC source: 0001731122-21-001126 · ownership.xml · derivative · entry 7 Boenisch Sandra · CIK 0001655366 · PFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2027-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options subject to this grant vested quarterly over a three-year period commencing on June 30, 2017. Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 01:45 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 106,696 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001731122-21-001126 · ownership.xml · derivative · entry 6 Boenisch Sandra · CIK 0001655366 · PFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,696 shares Expires 2026-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 01:45 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.68 | $0.00 |
DisclosureSEC source: 0001731122-21-001126 · ownership.xml · derivative · entry 5 Boenisch Sandra · CIK 0001655366 · PFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options subject to this grant vested quarterly over a three-year period commencing on December 31, 2015. Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 01:45 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | SaleCommon Stock | 166,696 | $26.53 | $4,422,444.88 |
DisclosureSEC source: 0001731122-21-001126 · ownership.xml · nonDerivative · entry 4 Boenisch Sandra · CIK 0001655366 · PFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,963 Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 01:45 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 35,000 | $5.92 | $207,200.00 |
DisclosureSEC source: 0001731122-21-001126 · ownership.xml · nonDerivative · entry 3 Boenisch Sandra · CIK 0001655366 · PFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 01:45 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 106,696 | $3.28 | $349,962.88 |
DisclosureSEC source: 0001731122-21-001126 · ownership.xml · nonDerivative · entry 2 Boenisch Sandra · CIK 0001655366 · PFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 01:45 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 25,000 | $5.68 | $142,000.00 |
DisclosureSEC source: 0001731122-21-001126 · ownership.xml · nonDerivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 19:26 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001731122-21-000012 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common stock · 50,000 shares Expires 2030-12-30 F1 · derivative.exercise_date: The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2/3 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-20-000024 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-01-06 F1 · derivative.exercise_date: The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 23:48 UTC | DESTINY MEDIA TECHNOLOGIES INC DSNY · Entity 8237 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001062993-19-003838 · form4.xml · derivative · entry 3 Boenisch Sandra · CIK 0001655366 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 20,000 shares Expires 2022-12-13 F1 · kind: The reporting person agreed to cancellation of options granted on December 13, 2017 and amended June 25, 2019 in exchange for a new option having a lower exercise price. F2 · derivative.exercise_date: The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 23:48 UTC | DESTINY MEDIA TECHNOLOGIES INC DSNY · Entity 8237 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001062993-19-003838 · form4.xml · derivative · entry 2 Boenisch Sandra · CIK 0001655366 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 10,000 shares Expires 2022-12-13 F1 · kind: The reporting person agreed to cancellation of options granted on December 13, 2017 and amended June 25, 2019 in exchange for a new option having a lower exercise price. F2 · derivative.exercise_date: The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 23:48 UTC | DESTINY MEDIA TECHNOLOGIES INC DSNY · Entity 8237 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001062993-19-003838 · form4.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common · 30,000 shares Expires 2022-12-13 F1 · kind: The reporting person agreed to cancellation of options granted on December 13, 2017 and amended June 25, 2019 in exchange for a new option having a lower exercise price. F2 · derivative.exercise_date: The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017. Read SEC document |
| August 31, 2019 Filed Oct 4, 2019 19:12 UTC | DESTINY MEDIA TECHNOLOGIES INC DSNY · Entity 8237 | GrantCOMMON | 5,643 | $1.25 | $7,053.75 |
DisclosureSEC source: 0001062993-19-003822 · form5.xml · nonDerivative · entry 1 Boenisch Sandra · CIK 0001655366 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,984 F1 · kind: Purchased under Employee Stock Purchase Plan, which transactions are exempt under Rule 16b-3(c) of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.98 to $1.50, inclusive. The reporting person undertakes to provide to Destiny Media Technologies Inc., any security holder of Destiny Media Technologies Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The weighted average price reported above was converted from the Canadian weighted average price of C$1.66 to USD using an exchange rate of CAD $1.3294=USD $1.00. F3 · balance_after: Reflects 5:1 stock consolidation effected by Destiny Media Technologies Inc. on September 13, 2019. Read SEC document |
| June 25, 2019 Filed Oct 4, 2019 19:12 UTC | DESTINY MEDIA TECHNOLOGIES INC DSNY · Entity 8237 | Disposition to issuerSTOCK OPTION (RIGHT TO BUY) · Derivative | 30,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001062993-19-003822 · form5.xml · derivative · entry 4 Boenisch Sandra · CIK 0001655366 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: COMMON · 30,000 shares Expires 2022-12-13 F4 · kind: The reporting person agreed to cancellation of an option granted on December 13, 2017 exchange for new options having a lower exercise price. F5 · derivative.exercise_date: The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017. F3 · derivative.underlying_shares: Reflects 5:1 stock consolidation effected by Destiny Media Technologies Inc. on September 13, 2019. Read SEC document |
| June 25, 2019 Filed Oct 4, 2019 19:12 UTC | DESTINY MEDIA TECHNOLOGIES INC DSNY · Entity 8237 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 20,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001062993-19-003822 · form5.xml · derivative · entry 3 Boenisch Sandra · CIK 0001655366 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: COMMON · 20,000 shares Expires 2022-12-13 F4 · kind: The reporting person agreed to cancellation of an option granted on December 13, 2017 exchange for new options having a lower exercise price. F5 · derivative.exercise_date: The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017. F3 · derivative.underlying_shares: Reflects 5:1 stock consolidation effected by Destiny Media Technologies Inc. on September 13, 2019. Read SEC document |
| June 25, 2019 Filed Oct 4, 2019 19:12 UTC | DESTINY MEDIA TECHNOLOGIES INC DSNY · Entity 8237 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 10,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001062993-19-003822 · form5.xml · derivative · entry 2 Boenisch Sandra · CIK 0001655366 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: COMMON · 10,000 shares Expires 2022-12-13 F4 · kind: The reporting person agreed to cancellation of an option granted on December 13, 2017 exchange for new options having a lower exercise price. F5 · derivative.exercise_date: The options are vesting in equal monthly installments over a two-year period which commenced on December 31, 2017. F3 · derivative.underlying_shares: Reflects 5:1 stock consolidation effected by Destiny Media Technologies Inc. on September 13, 2019. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 23:27 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001213900-19-010249 · s113104_form4.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-06-04 F1 · derivative.exercise_date: The options shall vest upon the achievement by the Company of 100% patient enrollment in the Company's Phase 2b/3 Alzheimer's disease and Phase 2 Parkinson's disease dementia clinical trials. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:29 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 27,300 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001615774-18-010439 · s113104_form4.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,300 Underlying: Common Stock · 27,300 shares Expires 2028-10-01 F1 · derivative.exercise_date: The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:23 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001615774-18-004023 · s110300_form4.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-05-15 F1 · derivative.exercise_date: The options shall vest upon the achievement of certain performance criteria in connection with clinical trial milestones. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 21:39 UTC | DESTINY MEDIA TECHNOLOGIES INC DSNY · Entity 8237 | OtherCommon | 46,207 | $0.26 | $12,013.82 |
DisclosureSEC source: 0001062993-18-000422 · form4.xml · nonDerivative · entry 1 Boenisch Sandra · CIK 0001655366 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,707 F1 · kind: Purchased under Employee Stock Purchase Plan, which transaction is exempt under Rule 16b-3(c) of the Securities Exchange Act of 1934. F2 · price: $0.3212 Canadian Dollars, based on exchange rate of 0.8135. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:11 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001615774-17-007357 · s108450_form4.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-12-13 F1 · derivative.exercise_date: The options shall vest quarterly over a three-year period commencing on March 31, 2018. Read SEC document |
| May 12, 2017 Filed May 15, 2017 21:14 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $5.92 | $0.00 |
DisclosureSEC source: 0001615774-17-002450 · s106223_form4.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-05-12 F1 · derivative.exercise_date: The options shall vest quarterly over a three-year period commencing on June 30, 2017. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 21:14 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 106,696 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001615774-16-007380 · s104215_form4.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,696 Underlying: Common Stock · 106,696 shares Expires 2026-09-22 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.